Clinical Research Directory

Inclusion Criteria: * Age ≥16 years; * Definitive (certainty) or probable diagnosis of FH by the Dutch MEDPED criteria; * Using one of the following treatment regimens for ≥6 weeks according to age: \>= 20 years -\> simvastatin 40 mg; lovastatin 40 mg; pravastatin 80 mg; atorvastatin 20 mg; rosuvastatin 10 mg; pitavastatin 4 mg; fluvastatin 80 mg; atorvastatin 40- 80 mg; rosuvastatin 20 - 40 mg; atorvastatin 40 - 80 mg + ezetimibe 10mg; rosuvastatin 20 - 40 mg + ezetimibe 10mg; or simvastatin 40mg + ezetimibe 10mg. 16 to 19 years -\> simvastatin 10 - 40 mg; lovastatin 10 - 40 mg; pravastatin 10 - 40 mg; atorvastatin 10 - 40 mg; rosuvastatin 5 - 40 mg; cholestyramine 4 to 16 mg; ezetimibe 10mg (in combination with statin). Exclusion Criteria: * Having a "possible" FH result according to the Dutch MEDPED criteria; * TG ≥ 500mg/dL up to 6 months before screening for the study; * Diagnosis of hypercholesterolemia due to a secondary cause recorded in the medical record; * Food allergies (foods, dyes, preservatives); * Contraindication to the use of phytosterols (for example: diagnosis of sitosterolemia); * HIV positive on treatment with detectable viral load or AIDS; * Chronic inflammatory or autoimmune diseases; * Known liver disease, chronic kidney disease on dialysis or pancreatitis (acute and chronic); * Cancer being treated or life expectancy \< 6 months; * Episode of acute coronary syndrome in the last 60 days; * Chemical dependency/alcoholism; * Chronic use of anti-inflammatories, anticonvulsants and immunosuppressive drugs; * Use of PCSK9 inhibitors (alirocumab, evolocumab, inclisiran); * Pregnancy or lactation; * Individuals who are unable to perform an anthropometric assessment, at the discretion of the investigator; * Grade III/severe obesity (body mass index \[BMI\] ≥40kg/m² for adults or percentile \>99.9 or z-score \>+3 according to WHO/2006 growth curves for BMI/Age indicator for adolescents); * Use of dietary supplements that may interfere with the outcomes of interest (dietary fiber modules, n-3 PUFA, essential fatty acids); * Participation in other randomized clinical trials; * Refusal to participate in the study, due to failure to sign the Free and Informed Consent Form.